linjc16/ctgov huggingface dataset:
Evaluating the Effect of an Evidence-Based One Page With Supplemental Visual Aids on the Knowledge and Perceptions of Blood Pressure Management Among Adults With Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate changes in patient knowledge of blood pressure management and perceptions of making lifestyle changes to manage their blood pressure after implementation of an evidence-based one-page teaching protocol with supplemental handouts and optional use of suggested apps and web sites.

Official Title
-----------------
Evaluating the Effect of an Evidence-Based One Page With Supplemental Visual Aids on the Knowledge and Perceptions of Blood Pressure Management Among Adults With Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Behavioral: Blood pressure education


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults from 18 to 75 years old Ability to self-consent English-speaking Able to read/write English Currently prescribed at least one medication for treatment of essential primary hypertension Exclusion Criteria: Adults unable to consent Individuals who are not yet adults (infants, children, teenagers) Pregnant women Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: BP Education<br>All participants enrolled receive blood pressure education. | Behavioral: Blood pressure education<br>* One page teaching protocol performed by pharmacy students; phone follow-up<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre & Post Survey & Knowledge Test | change in participant's knowledge of blood pressure management - as measured by a pre- and post-test of 10 multiple-choice questions Change in participant's perception of making lifestyle changes to manage their hypertension - measured via pre- and post-survey using a 1-5 Likert Scale rating usefulness of the program and educational resources provided; and questions about which lifestyle modifications were made by the participant, which apps were used by the participant (if applicable), and which educational handouts were used by the participant | 8 weeks |
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
To demonstrate that CT-P13 is equivalent to China-approved Remicade at Week 14, in terms of efficacy as determined by clinical response according to the change from baseline in disease activity.

Official Title
-----------------
A Randomized, Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Biological: CT-P13
* Biological: Remicade


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Has a diagnosis of rheumatoid arthritis Has active disease as defined in DAS28 Criteria Exclusion Criteria: Has a history of tuberculosis (TB) or a current diagnosis of TB Has previously received a biological agent Has previously received a tumor necrosis factor alpha (TNF α) inhibitor Allergies to any of the excipients of infliximab or hypersensitivity to murine and/or human proteins or immunoglobulin products Pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CT-P13<br> | Biological: CT-P13<br>* 3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid<br>|
| Active Comparator: China-approved Remicade<br> | Biological: Remicade<br>* 3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy assessment: DAS28 (CRP) at Week 14 | Clinical response according to the change from baseline in disease activity as measured by the Disease Activity Score using 28 joint counts (DAS28) (C-reactive protein[CRP]) | Week 14 |
Behavioral Abnormalities in Dysphonic Children

Study Overview
=================
Brief Summary
-----------------
we will assess dysphonic children as regard presence of behavioral abnormalities and then receive voice therapy

Official Title
-----------------
Behavioral Abnormalities in Dysphonic Children

Conditions
-----------------
Dysphonia

Intervention / Treatment
-----------------
* Behavioral: voice therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
inclusion criteria : dysphonic children age 6-12 years exclusion criteria: age less than 6 years and more than 12 years, hearing impaired, neurological abnormalities.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: control group<br>dysphonic children without behavioral abnormalities | Behavioral: voice therapy<br>* sessions of voice therapy<br>|
| Other: study group<br>dysphonic children with behavioral abnormalities | Behavioral: voice therapy<br>* sessions of voice therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in child behavior checklist | scale assessing behavioral abnormalities of child as anxiety symptoms,depression symptoms,somatic symptoms,social problems,thought problems,attention problems,aggressive behavior and rule breaking behavior through asking parent of the child with minimal score 24 maximal score 100 | Baseline (before sessions) and after 3 months of sessions | 
| computerized speech lab. | voice sample will be taken from child including vowels and connecting speech will be analyzed by computerized speech lab to evaluate change in acoustic parameters as jitter,shimmer,fundamental frequency and noise to harmonic ratio | Baseline (before sessions) and after 3 months of sessions |
Quality of Life After Conservative and Surgical Treatment of Pelvic Organ Prolapse

Study Overview
=================
Brief Summary
-----------------
This is an observational study that gives baseline and follow-up information, that does not directly influence the allocation of patients to various treatment Options (conservative and surgical therapy of Pelvic Organ Prolapse) but the knowledge gained of the data will help to develop treatment strategies.

Official Title
-----------------
Quality of Life After Conservative and Surgical Treatment of Pelvic Organ

Conditions
-----------------
Pelvic Organ Prolapse, Quality of Life, Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Pelvic Organ Prolapse (POP) Exclusion Criteria: < 18 years Patients unable to understand an informed consent Patients unwilling to participate emergency operations pregnancy Overactive Bladder without descensus Stool incontinence without POP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| symptom change assessed by German Pelvic Floor Questionnaire (GPFQ) | Change in the symptom scores assessed by the German Pelvic Floor Questionnaire (GPFQ) by at least 1.0 points 6 months post-therapy. The GPFQ does contain the domains bladder function, bowel function, prolapse and sexual symptoms. In each domain a total of 10 points may be reached. The maximum symptom score for the entire questionnaire are 40 points. The minimal symptom score is 0 points. The minimal important difference (MID) for patients with Pelvic Organ Prolapse (POP) is 1.0 points. A decrease of the symptom score by at least 1 point reflects a meaningful improvement. | before therapy and up to 5 years post-therapy |
Visual Function After Implantation of AcrySof® Toric Lens

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the postoperative visual function of Taiwanese patients following bilateral or unilateral AcrySof Toric Intraocular Lens (IOL) implantation.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: AcrySof Toric Intraocular Lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prospective subjects should be adults and may be of any race and gender, and diagnosed with cataracts. Subject must require extraction of cataracts followed by implantation of a posterior chamber intraocular lens. All subjects must have between 0.75 - 2.0 Diopter (D) of astigmatism preoperatively as measured by keratometry readings. For any second eye surgery in bilateral AcrySof Toric patients, it should be performed at least one week following the first eye implant but no longer than one month after the first implant. Exclusion Criteria: Subjects with pre-existing conditions that could skew the results should be excluded from the Study. AcrySof® Toric product inserts under Precautions for subject groups that should be excluded from this Study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Toric<br>AcrySof Toric Intraocular Lens (IOL) | Device: AcrySof Toric Intraocular Lens<br>* Implantation of the AcrySof Toric Intraocular Lens (IOL)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Refractive Cylinder |  | Pre-Operative Day, 1 Month Postoperative, 3 Month Postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncorrected distance visual acuity (UCDVA) |  | Pre-Operative Day, 1 Month Postoperative, 3 Month Postoperative | 
| Best corrected distance visual acuity (BDCVA) |  | Pre-operative, 1 month postoperative, 3 months postoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cataract
Efficacy of Tomosynthesis in the BIRADS 3 Population

Study Overview
=================
Brief Summary
-----------------
There are three main objectives, centering on those patients targeted for surveillance imaging. The first objective is to compare image quality and specificity of breast tomosynthesis and conventional 2D mammography in a BIRADS 3 diagnostic population. The second objective is to compare image quality and ability to determine post-surgical and post-radiation changes from recurrence in a post-cancer subset of a BIRADS 3 population having undergone conservation therapy (lumpectomy with or without radiation. The final objective is to compare image quality and the ability to determine chemoresponsiveness in a post-cancer subset of a BIRADS 3 population, who are undergoing neoadjuvant chemotherapy.

Official Title
-----------------
The Efficacy of Tomosynthesis in the BIRADS 3 Population Including Surveillance of Patients in the Treatment or Post-Treatment for Breast Cancer

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: GROUP 1 female of any race and ethnicity 35 years or older after routine and diagnostic imaging, subject is categorized as a BI-RADS 3 and will undergo study imaging within 30 days of routine or diagnostic imaging. subject is returning for surveillance imaging after a categorization of a BI-RADS 3 and will undergo study imaging within 30 days of surveillance imaging GROUP 2 female of any race and ethnicity 26 years or older subject has completed cancer treatment and is currently categorized as a BI-RADS 3 for surveillance imaging subject will undergo study imaging within 30 days of surveillance imaging GROUP 3 female of any race and ethnicity 26 years or older subject is currently undergoing cancer treatment and is currently categorized as a BI-RADS 3 for surveillance imaging OR subject will undergo study imaging within 30 days of surveillance imaging Exclusion Criteria: GROUP 1, 2 and 3 subjects unable or unwilling to participate subjects who are unable or unwilling to tolerate compression subjects who are pregnant or who think they may be pregnant subjects who are breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 26 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast cancer<br>Patients in treatment or post-treatment for breast cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to see if Breast Tomosynthesis, a three-dimensional (3D) imaging study is more accurate than standard mammography (a two-dimensional (2D) study). |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, Three dimensional versus two dimensional, Breast cancer surveillance, Tomosynthesis
Levonorgestrel-releasing Intrauterine System and Tubal Ligation

Study Overview
=================
Brief Summary
-----------------
Today tubal sterilization is a simple, safe, and cost-effective method of achieving long-term contraception. Sterilization is an ideal method of permanent contraception in developing countries where access to health care providers is limited. The percentage of women who use sterilization as a method of contraception rises from about 5% between 20 and 24 years of age to almost 50% for those between 40 and 44 years of age. The most widely touted and most significant health benefit of tubal sterilization appears to be a reduced risk of ovarian cancer. Post-tubal ligation syndrome includes pain during intercourse, aching lower back, premenstrual tension syndrome, uterine hemorrhage, and absence of menstruation. The syndrome is caused by blood circulation problems in and around the Fallopian tubes and ovaries, pressure on nerves, and intrapelvic adhesion. Since the symptoms of this syndrome are mild, simple symptomatic treatment is sufficient in most cases. In some cases, however, hysterectomy may be necessary.

Official Title
-----------------
Levonorgestrel-releasing Intrauterine System: A Emerging Tool for Conservative Treatment of Pain and Bleeding After Tubal Ligation

Conditions
-----------------
Tubal Ligation

Intervention / Treatment
-----------------
* Device: Levonorgestrel-releasing intrauterine system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged from 30-40 year Woman subjected to tubal ligation Women 12 month postpartum Non lactating women Nomedical disorders Exclusion Criteria: contraindication for Levonorgestrel-releasing Intrauterine System Women with any uterine or ovarian pathology women refuse to participate

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Levonorgestrel-releasing intrauterine system<br> | Device: Levonorgestrel-releasing intrauterine system<br>* Levonorgestrel-releasing intrauterine system will be inserted during the menstrual cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The level of pain from before to 6 months after levonorgestrel-releasing intrauterine system insertion | visual analogue scale from 0 (minimum value) to 10 (maximum value) | 6 months |
Analysis of Complementary Exams Prescriptions From an Emergency Unit of a University Hospital

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the appropriateness of prescribing additional tests in the emergency unit of the University Hospital of Monastir.

Detailed Description
-----------------
The objective of this study is to evaluate the appropriateness of prescribing additional tests in the emergency unit of the University Hospital of Monastir.

Official Title
-----------------
Complementary Exams in Emergency Department

Conditions
-----------------
Complementary Investigations

Intervention / Treatment
-----------------
* Other: sensitization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients consulting Emergency Department of Monastir aged more than 1 year Exclusion Criteria: age < 1 year

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| before intervention<br>1000 patients befor sensitization | Other: sensitization<br>* sensitization of doctor to decrease the prescription of abuse exams<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The analysis focused on the appropriateness or otherwise of the complementary exams |  | The analysis focused on the appropriateness or otherwise of the complementary exams | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
complementary exam
Research on the Application and Mechanism of New Biological Probes in Biomedicine

Study Overview
=================
Brief Summary
-----------------
Fluorescence is one of the most commonly used research and detection techniques in the field of biomedical science. The characteristics of fluorescent probe directly affect the performance and application of fluorescence analysis and imaging. Aggregation-Caused Quenching has limited the application of traditional fluorescent probes to some extent. This project intends to systematically evaluate the detection efficiency of new methods through the detection of biomarkers in clinical samples and the comparison with the detection methods of traditional biomarkers, so as to provide theoretical and experimental basis for the establishment of fast and simple biomarker detection technologies with new biological probes.

Official Title
-----------------
Research on the Application and Mechanism of New Biological Probes in Biomedicine

Conditions
-----------------
Tumors, Cardiovascular Diseases, Respiratory System Diseases, Digestive System Diseases, Endocrine System Diseases, Metabolic Diseases, Immune System Diseases, Urinary System Diseases, Nervous System Diseases, Blood Diseases, Infectious Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sign the informed consent form voluntarily. Age 18-70 years old. High expression (positive) group: The results of multiple laboratory tests indicate that the marker is higher than the normal range. Low expression (negative) healthy volunteer group: those with no underlying diseases and no abnormalities in the physical examination. Have routine examination to check the remaining body fluid samples, and the body fluid samples are not contaminated. Exclusion Criteria: Accompanied by other inflammations. The data of the subject is not complete, or the collection of cases is incomplete due to other reasons. The researcher judged that it was not suitable to participate in this research.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| those with a condition<br> | Diagnostic Test: No intervention<br>* No intervention<br>|
| those without a condition<br> | Diagnostic Test: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| signal intensity of the probes |  | one day |